Bateman Horne Center conducts high-standard, quality clinical research and trials, assuring the research question is answered in a reliable, valid, and unbiased manner, while protecting the rights and welfare of human subjects. Bateman Horne Center follows standardized procedures and processes, ensuring regulatory compliance and the safety of human subjects.
If you are an organization that would like to partner on a clinical research project please email [email protected]
Participate in Research!
Our research department is partnering with ChronicleBio to better understand under-researched chronic conditions such as POTS, ME/CFS, and Long COVID.By collecting biological samples—including saliva, blood, and urine—and linking them with real patient data, researchers can gain insight into what’s driving these illnesses and work toward more targeted treatments.
All samples are stored securely in ChronicleBio’s biobank and used exclusively for medical research. This study includes three in-person visits, with sample collection occurring at three-month intervals. At this time, we are enrolling participants who have, or believe they may have, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
Individuals interested in participating are invited to complete a brief eligibility questionnaire.
For additional details about this study, please contact our Research Coordinators at 801-532-8311.
Completed Studies
- FORTRESS Study: Trial of IMC-1 for the Treatment of Fibromyalgia
- Exagen-Better Study (20-FMS1-Better): Fibromyalgia Study
- A Study to Evaluate the Efficacy and Safety of TXN-102 SL in Patients with Fibromyalgia (RELIEF)
- Defining Posture Contributors to Post-Exertional Malaise
- Multisite Clinical Assessment of CFS: A CDC-funded study to understand ME/CFS
- InTiME: Pilot Phase 1/2 Clinical Trial To Investigate CT38 In the Treatment of ME/CFS
- Restore: A clinical trial of droxidopa for neurogenic orthostatic hypotension
- Juvenile Fibromyalgia Study (Ages 13-17): Duloxetine versus placebo
- Fibromyalgia Study (Ages 18-65): DS-5565 compared to pregabalin and placebo
- Fibromyalgia Study Low-dose cyclobenzaprine tablets (TNX-102 Phase III)
- Fibromyalgia: Neuropoint Device delivering RINCE treatment
- Chronic Fatigue Syndrome: Nutraceuticals & Low-dose methylphenidate
- Fibromyalgia: IMC-1 combination versus placebo
- Juvenile Fibromyalgia: Lyrica/pregabalin versus placebo
- Chronic Fatigue Syndrome: Poly I: Poly C12U IV drug (Ampligen) open label study
- Fibromyalgia: Low-dose sublingual cyclobenzaprine tablets (Phase II)
Lucinda Bateman, MD, is a renowned clinician, researcher, and educator. Her Johns Hopkins University Medical School training instilled an approach to care that she has employed throughout her career – the patient comes first and the unknown or unexplained does not equate to a lack of proper and compassionate care. Since starting her own practice in 2000, she has served on six boards or committees, been the principal investigator for 45 studies, authored/coauthored 40 journal articles, served as adjunct instructor and adjunct assistant professor in the University of Utah Departments of Preventative Medicine, Internal Medicine, and Anesthesiology, and lectured around the world.